Mumbai, Maharashtra, India, March 2025 – Dr. Rajeev Agarwal has been appointed as President – Ferticare Cluster at Gufic Biosciences Ltd., bringing with him over 30 years of experience in the pharmaceutical industry. His deep expertise in gynecology therapies, sales, and marketing will be instrumental in driving the growth of the Ferticare Cluster, strengthening market presence, and advancing reproductive healthcare solutions.
Before joining Gufic Biosciences Ltd., Dr. Rajeev Agarwal served as President at Bharat Serums and Vaccines Limited for nearly two years, where he led the Women’s Healthcare RX Cluster and played a crucial role in expanding the company’s footprint in gynecology and fertility solutions.
Prior to that, he spent over five years at Emcure Pharmaceuticals Limited, where he held multiple leadership roles, including Director, Associate Director, General Manager, BU Head, and Deputy General Manager. During his tenure, he headed Emcure’s largest division with a 650-member team and a turnover of ₹350 crore, successfully built a ₹50 crore brand within the first year, and played a key role in scaling up key brands like Orofer XT, Pause, and Assomex.
Earlier in his career, he was associated with Alembic Pharmaceuticals Limited as Zonal Sales Manager (ZSM) and spent nearly five years at Zydus Group as Senior Brand Manager, focusing on strategic sales and marketing in the gynecology segment.
His longest tenure of over seven years was at Ferring Pharmaceuticals, a global leader in IVF and peptide-based therapies, where he served as Senior Manager, contributing significantly to the company’s market leadership in reproductive healthcare.
Dr. Rajeev Agarwal holds a Doctorate in Management, an LLB from Bareilly College, and a B.Sc from Kumaon University. His academic excellence, combined with his vast industry experience, has allowed him to develop a strong strategic vision for therapy market development, sales growth, and brand leadership.
Throughout his career, he has successfully launched and positioned breakthrough products such as Menagon, Decapetyl Depot, Naturogest, and Orofer XT, making significant contributions to women’s healthcare and fertility treatments.
At Gufic Biosciences, he will focus on driving product innovation, expanding market reach, and strengthening the company’s position in reproductive healthcare, ensuring that cutting-edge fertility solutions reach a broader audience.
About Gufic Biosciences Ltd.
Founded over five decades ago, Gufic Biosciences Ltd. is a leading pharmaceutical company specializing in critical care medicines, fertility and parenthood solutions, nutraceuticals, and orthopedics & gynecology treatments. The company has pioneered Lyophilization technology and operates a state-of-the-art manufacturing facility accredited by global regulatory bodies like EU-GMP, ANVISA-Brazil, TGA-Australia, HC-Canada, and SAHPRA-South Africa.
With a strong global presence in over 25 countries, Gufic Biosciences is committed to delivering high-quality pharmaceutical solutions and innovating in reproductive healthcare. The appointment of Dr. Rajeev Agarwal aligns with the company’s strategy to enhance business operations, expand its market leadership, and strengthen customer engagement in the fertility segment.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
